<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="685">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05152238</url>
  </required_header>
  <id_info>
    <org_study_id>ZKSJ0142</org_study_id>
    <nct_id>NCT05152238</nct_id>
  </id_info>
  <brief_title>ITP Registry and Accompanying Biospecimen Collection</brief_title>
  <acronym>ITP-Registry</acronym>
  <official_title>Multicenter National ITP Registry and Accompanying Biospecimen Collection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jena University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Dresden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Orphan Biovitrum</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Grifols Biologicals, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jena University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this ITP registry is to collect clinical information, including biosampling,&#xD;
      from consenting patients with a variety of ITPs at different points in the course of their&#xD;
      disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immune thrombocytopenia (ITP) is a rare hematologic disorder that can lead to a greater risk&#xD;
      of bleeding or a prolonged bleeding time due to an autoimmune-mediated deficiency of&#xD;
      platelets.&#xD;
&#xD;
      In recent years, new treatment options for patients with immune thrombocytopenia have&#xD;
      emerged.&#xD;
&#xD;
      The results of published clinical studies on ITP can only be used for broad patient care to a&#xD;
      limited extent, as they are designed for a patient population with clearly defined inclusion&#xD;
      and exclusion criteria. Real world data collected from this registry will help to better&#xD;
      understand the diagnosis and therapy of ITP patients in everyday treatment and to more&#xD;
      effectively direct individual patients to optimal therapy, thus improving their outcomes.&#xD;
&#xD;
      By collecting biospecimens, this project will contribute new knowledge to the study of ITP&#xD;
      through standardized, systematic, and high-quality collection and storage of patient samples&#xD;
      and associated data.&#xD;
&#xD;
      The registry collects clinical data from patients diagnosed with ITP at defined points in the&#xD;
      course of the disease. The Data collection includes a range of clinical measures,&#xD;
      disease-related factors, treatment/treatment course and outcomes, complications during&#xD;
      treatment and Qol, fatigue scoring and survival data (up to 5 years).&#xD;
&#xD;
      The data are collected prospectively. In addition, patients can be included retrospectively&#xD;
      up to 12 months after the initial diagnosis if continuous documentation can be provided at&#xD;
      the treatment centre. In both cases, a written declaration of consent is obligatory.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 29, 2021</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>epidemiological data on ITP - Incidence</measure>
    <time_frame>At enrollment</time_frame>
    <description>Incidence: number of reported ITP, estimate incidence by zip code area</description>
  </primary_outcome>
  <primary_outcome>
    <measure>epidemiological data on ITP - Age</measure>
    <time_frame>At enrollment</time_frame>
    <description>Age (year of birth)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>epidemiological data on ITP - Sex distribution</measure>
    <time_frame>At enrollment</time_frame>
    <description>Sex distribution: female, male</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the causes of ITP</measure>
    <time_frame>At enrollment</time_frame>
    <description>causes of ITP in primary/secondary form (medical induced, autoimmune disease, Lymphoma / malignancy, infection, upon vaccination, others)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ITP treatment type received</measure>
    <time_frame>5 years</time_frame>
    <description>Medical therapies received</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Remission</measure>
    <time_frame>5 years</time_frame>
    <description>Remission Status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recording of clinical characteristics of affected patients - Disease stage</measure>
    <time_frame>At enrollment, 6 months, annually up to 5 years</time_frame>
    <description>bleeding severity WHO-CTCAE Grade 1-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording of clinical characteristics of affected patients- platelet counts</measure>
    <time_frame>At enrollment, 6 months, annually up to 5 years</time_frame>
    <description>platelet counts in Gpt/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording of clinical characteristics of affected patients -disease manifestation at diagnosis</measure>
    <time_frame>At enrollment</time_frame>
    <description>Localisation of bleeding and severity (WHO-CTCAE Grading)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>At enrollment, 6 months, annually up to 5 years</time_frame>
    <description>Bleeding events (yes, no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>thromboembolic events</measure>
    <time_frame>At enrollment, 6 months, annually up to 5 years</time_frame>
    <description>thromboembolic events (no, Deep vein thrombosis, acute pulmonary artery embolism, other)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life questionaire</measure>
    <time_frame>At enrollment, 6 months, annually up to 5 years</time_frame>
    <description>ILQI questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fatigue assessment</measure>
    <time_frame>At enrollment, 6 months, annually up to 5 years</time_frame>
    <description>FACIT-F questionaire: subscale fatigue (only last 13 questions)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters ANA</measure>
    <time_frame>At enrollment, 6 months, annually up to 5 years</time_frame>
    <description>ANA (negative/positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters APL-Antibodies</measure>
    <time_frame>At enrollment, 6 months, annually up to 5 years</time_frame>
    <description>APL-Antibodies (negative/positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters Lupus-Antibodies</measure>
    <time_frame>At enrollment, 6 months, annually up to 5 years</time_frame>
    <description>lupus-Antibodies (negative/positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters platelet autoantibodies</measure>
    <time_frame>At enrollment, 6 months, annually up to 5 years</time_frame>
    <description>platelet autoantibodies (negative/positive)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory parameters helicobacter pylori</measure>
    <time_frame>At enrollment, 6 months, annually up to 5 years</time_frame>
    <description>helicobacter pylori (negative/positive)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      18 mL whole blood (peripheral venipuncture) and 9 ml bone marrow&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Immune thrombocytopenia (ITP) which is a rare hematologic disorder that can&#xD;
        lead to a greater risk of bleeding or a prolonged bleeding time due to an&#xD;
        autoimmune-mediated deficiency of platelets. There is a distinction between a primary form,&#xD;
        in which no triggering cause is identifiable, and secondary forms, which may for example&#xD;
        occur in the context of systemic autoimmune diseases or drug-induced.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary or secondary Immune Thrombocytopenia (ITP)&#xD;
&#xD;
          -  Age â‰¥18 years&#xD;
&#xD;
          -  signed declaration of consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  diagnoses that cannot be reconciled with the diagnosis of ITP (esp. heparin-induced&#xD;
             thrombocytopenia, pregnancy-associated thrombocytopenia, pseudothrombocytopenia)&#xD;
&#xD;
          -  no informed consent possible (this covers patients who are unable to understand the&#xD;
             nature and scope of participation)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Stauch, Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Jena University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karolin Trautmann-Grill, Dr. med.</last_name>
    <role>Study Director</role>
    <affiliation>Dresden Univeristy Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Stauch, Dr. med.</last_name>
    <phone>0049-3641-9326864</phone>
    <email>thomas.stauch@med.uni-jena.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karolin Trautmann-Grill, Dr. med.</last_name>
    <phone>0049-351-45818229</phone>
    <email>Karolin.Trautmann@uniklinikum-dresden.de</email>
  </overall_contact_backup>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>December 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jena University Hospital</investigator_affiliation>
    <investigator_full_name>Thomas Stauch</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no validated data sharing procedure at the university hospital Jena. But of course it is planned to share the results with scientific community and publish the data in a scientific journal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

